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Abstract
Background: In vivo proton magnetic resonance spectroscopy (1H-MRS) studies on brain in HIV infected patients
have shown significant alteration in neuro-biochemicals.
Methods: In this study, we measured the neuro-biochemical metabolites from the left frontal white matter (FWM)
and left basal ganglia (BG) caudate head nucleus in 71 subjects that include 30 healthy controls, 20 asymptomatic
HIV and 21 HIV patients with CNS lesion. Proton MR spectra were acquired at 3 T MRI system and the concentration
(institutional units) of tNAA (N-acetylaspartate, NAA + N-acetylaspartylglutamate, NAAG), tCr (Creatine, Cr +
phosphocreatine, PCr), choline containing compounds (tCho), glutamate + glutamine (Glx) and lipid and
macromolecules at 0.9 ppm were determined using LC Model.
Results: In BG, the concentration of tNAA (6.71 ± 0.64) was decreased and in FWM, the concentration of Glx
(20.4 ± 7.8), tCr (9.14 ± 3.04) and lipid and macromolecules at 0.9 ppm (8.69 ± 2.96) were increased in HIV
patients with CNS lesion. In healthy controls, the concentration of tNAA in BG was 7.31 ± 0.47 and concentration of Glx,
tCr and lipid and macromolecules in FWM were 15.0 ± 6.06, 6.95 ± 2.56, 5.59 ± 1.56, respectively.
Conclusion: Reduced tNAA in BG suggests neuronal loss in HIV patients with CNS lesion while increased Glx in FWM
may suggest excito-toxicity. In addition, increased levels of tCr in FWM of HIV patients were observed. The study
indicates region specific metabolic changes in tNAA, tCr and Glx in brain of HIV infected patients.
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Background
Human immunodeficiency virus (HIV) continues to be a
major global public health issue. Approximately 36.9
[34.3–41.4] million people were living with HIV in 2014
whereas 2.0 [1.9-2.2] million people died of HIV related
illnesses in 2014 and more than 95 % of all HIV-infected
people now live in developing world [1]. India ranks
third with the estimated number of people living with
HIV/AIDS is approximately 2.089 million (2012) with an
estimated adult (15–49 age group) HIV prevalence of
0.27 % in 2011 [2].
Central nervous system (CNS) involvement in HIV
can occur both early as well as late. Early involvement is
characterized by impaired abstracting ability, learning
difficulties and slow speed of information processing.
Late involvement of CNS can be either by neoplasms or
opportunistic infections [3].
Opportunistic infection includes toxoplasmosis,
cryptococcosis, progressive multifocal leucoencephalopa-
thy and tuberculosis. Neoplasms include primary CNS
lymphoma, Kaposi’s sarcoma and result of HIV-1 infec-
tion includes aseptic meningitis, HIV-associated neuro-
cognitive impairment, including HIV encephalopathy/
AIDS dementia complex [4].
MRS studies of brain have reported change in metab-
olite levels in HIV patients. Many studies have reported
changes in N-acetylasparatate (NAA) and creatine (Cr)
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levels in different regions of brain, however, the results
reported across these studies are not consistent and
sometimes contradictory [5–8]. Chong et al. [5] reported
that there is significant reduction in the mean NAA to
choline (Cho) ratio and NAA/Cr and an increase in
Cho/Cr was observed in HIV patients with immunosu-
pressed state and neurologic signs. Suwanwelaa et al. [7]
showed a statistically significant reduction in NAA/Cr
and NAA/Cho in centrum semiovale and thalamic areas
with no statistically significant difference in Cho/Cr and
mI/Cr in both the regions. The difference of NAA/Cr
was more pronounced in white matter than in gray mat-
ter. In addition, HIV infection has been linked with
neuro-cognitive impairment which has been shown to
result in increased excite-toxicity of glutamate [9, 10]. In
this context, glutamate concentration in brain has been
studied and found to be significantly increased in CSF,
plasma and brain tissues by using biochemical methods
in patients with HIV infection [9]. In the present study,
we have quantified changes in brain neuro-biochemical
levels in patients with HIV infection at 3.0 Tesla using




A total of 71 subjects were recruited under this study from
March 2014 to October 2015 including 30 healthy sub-
jects (Group 1), 20 HIV asymptomatic patients (Group 2)
and 21 HIV patients with CNS lesions (Group 3). Institute
Ethics Committee approved the study and written in-
formed consent was obtained from all the participants in
the study. In case of patients with altered sensorium, con-
sent was obtained from their relatives accompanying them
to the hospital. Healthy subjects were with no history of
high risk behavior, any prolonged medical or surgical
illness.
Physical examination and neurological evaluation
All the subjects underwent general physical examination
and detailed clinical neurological examination. Subjects
in Group 2 included sero-positive HIV patients with
CD4 count <500/ul and on anti-retroviral therapy
(ART), with normal neurological, neuropsychological
examination and no apparent CNS involvement and
were screened with the help of international HIV de-
mentia scale for any possible subclinical HIV associated
neuro-degeneration (HAND). Group 3 included HIV pa-
tient, with CNS involvement apparent on imaging (MR,
CT, PET), blood investigations or CSF study. Socioeco-
nomic status was derived by using Modified Kuppus-
wamy Scale last modified in 2012 [11]. For all
participants baseline respiratory rate, heart rate, blood
pressure and temperature were recorded.
Biochemical investigations
HIV status was confirmed for all subjects using ELISA
for HIV1 and HIV2 infection. In case of patients in
Group 2 and Group 3, most recent CD4 count was re-
corded. Since neuro-biochemical levels are affected by
dyslipidemia, diabetes and other derangement of normal
physiology, laboratory parameters were obtained for all
the participants. These included, complete blood counts,
kidney function test, liver function test, fasting lipid pro-
file and a fasting blood glucose level.
Magnetic resonance imaging and spectroscopy
All MR studies were carried out on a whole body 3 Tesla
MRI scanner (Achieva/Ingenia, Phillips Healthcare, The
Netherlands). Routine MRI of brain including multi-slice
T2-weighted axial images in three orthogonal planes and
diffusion-weighted images acquired with a standard head
coil. T2-weighted images in three orthogonal planes
were used to guide the localization of brain areas,
namely, left frontal lobe white matter (FWM) and left
basal ganglia (BG) (caudate head nucleus) for acquisition
of 1H MR spectra using single voxel MR spectroscopy.
In addition, voxel was placed on the CNS lesion in sub-
jects of Group 3. It was also ensured that the selected
voxel in the FWM or BG of HIV patients with CNS le-
sions did not include any lesion or part of it. Single voxel
1H MRS spectra were acquired with a point resolved
spectroscopy (PRESS) localization pulse sequence at an
echo time (TE) of 35 ms and a repetition time (TR) of
2000 ms with 64 or 128 scans. The voxel size used for
acquiring the MRS was 16 mm × 16 mm × 16 mm for
the FWM and 12 mm× 12 mm × 12 mm to 14 mm ×
14 mm × 14 mm for the BG depending upon the individ-
ual subject’s brain anatomy. The absolute concentrations
of neuro-biochemicals were estimated using Linear
Combination Model software (LC Model, version 6.3-1)
which performs deconvolution of spectra by using a
basis set of reference spectra [12]. The preprocessing of
MR spectra is fully automated by LCModel software
including phase, baseline and eddy current correction.
Water scaling method using unsuppressed water
spectrum acquired from the same voxel used for acquir-
ing water suppressed spectrum. Basis set of spectra (pro-
vided by the vendor) for individual neuro-biochemical
was used for automatic fitting routine for estimating the
absolute concentration and the Cramer-Rao Lower
Bounds values for each metabolite. The metabolite con-
centrations were reported as obtained directly from the
LCModel output and were not corrected for T1 and T2
relaxation effects. This method includes correction for
T2 relaxation time and the number of 1H nuclei contrib-
uting to the resonance peak. In the 1H MR spectrum ob-
tained, the main resonance peaks identified were arising
from tNAA (NAA +N-acetylaspartylglutamate, NAAG)
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at 2.0 ppm, tCr (Cr + phosphocreatine, PCr) at 3.0 ppm,
Cho-containing compounds (tCho) at 3.2 ppm, glutam-
ate + glutamine (Glx) at 2.2-2.4 ppm, myoinositol (mI) at
3.5 ppm and lipid/macromolecule (Lip09 +MM09) at
0.9 ppm. These resonances were analyzed to estimate
the concentration (in institutional units) of respective
metabolite and the Cramer-Rao lower bounds for all me-
tabolites analyzed in the study were below 15 %.
Statistics
Data was analysed by Stata 12 (Statacorp 4905, Lakeway
Drive, College Station, Texas) and described by mean,
standard deviation, frequency and percentage. Karl-
Pearson/ Spearman correlation coefficient was used to
assess the correlation between two continuous variables.
Continuous variables were compared among the Group
by one way ANOVA followed by post-hoc comparison
with Bonferroni correction. p-value less than 0.05 was
considered as significant.
Results
Demographic profile and clinical features
Mean age among three Groups was not statistically differ-
ent with the mean age of Group 1 34.3 ± 12.5 years, Group
2, 37.0 ± 13.1 years and 37.3 ± 10.6 years in Group 3. 50
subjects (70.4 %) were male whereas 21 subjects (29.6 %)
were female, 48 subjects (67.6 %) were married and 23
subjects (32.4 %) were unmarried (Table 1).
The mean duration between ART initiation and MRS
study for Group 2 is 6.3 ± 5.9 months whereas for Group
3, most of the patients were examined within a month
of ART therapy except 3 patients which were studied at
3, 38 and 144 months. However, it is difficult to know
the exact time of HIV infection.
Table 1 Comparison of baseline characteristics among three groups
Variable Healthy controls Asymptomatic HIV HIV with CNS lesion Total
Group 1 Group 2 Group 3
n = 30 n = 20 n = 21
Gender
Male 19 11 20 50 (70.42 %)
Female 11 09 01 21 (29.58 %)
Marital status
Married 16 17 15 48 (67.61 %)
Unmarried 14 03 06 23 (32.39 %)
Socioeconomic status
Upper (I) 17 02 01 20 (28.17 %)
Upper Middle (II) 06 03 02 11 (15.49 %)
Lower Middle (III) 02 05 03 10 (14.08 %)
Upper Lower (IV) 04 06 15 25 (35.21 %)
Lower (V) 01 04 00 05 (07.04 %)
High risk behavior
None 30 00 00 30
Not specified 00 04 01 05
Heterosexual intercourse 00 13 18 31
I.V. needle sharing 00 00 02 02
Blood transfusion 00 01 00 01
Tattooing 00 01 00 01
From spouse 00 01 00 01
Presenting complaints
None 30 00 00 30
Fever 00 11 08 19
Altered sensorium 00 00 11 11
Retrospective after spouse 00 03 00 03
Antenatal screening 00 02 00 02
Others 00 04 02 06
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No history of high risk behavior was seen in healthy
subjects; heterosexual intercourse was found to be most
common mode (31 patients) of HIV transmission in
Group 2 and Group 3. Other high risk behaviors in-
clude I.V. needle sharing (2 patients), blood transfusion
(1 patient), and tattooing (1 patient), from affected
spouse (1 patient) and in 5 HIV patients no specific eti-
ology could be elicited on the basis of the history. The
most common complaint in Group 2 was fever (55 %)
followed by other causes (20 %), retrospective diagnosis
after spouse (15 %) followed by during ante natal
check-up (10 %). In Group 3, the most common present-
ing complaint was altered sensorium (52.4 %), followed by
fever (30.1 %) and other causes (9.5 %) (Table 1) .There
was no significant difference in pulse rate and diastolic
blood pressure among three Groups studied. Systolic
blood pressure was significantly lower in Group 3 com-
pare to Group 1 and respiratory rate was significantly
higher in Group 3 compared to Group 1.
Biochemical parameters
CD4 count was significantly lower (p-value <0.001) in
Group 3 (106.95 ± 86.94 /ul) compared to Group 2 (257.40
± 129.09 /ul). Patients of Group 2 and Group 3 were found
to have significantly lower levels of hemoglobin (p-value
<0.0001), serum calcium (p-value < 0.0001), serum sodium
levels (p-value <0.0008) and serum albumin levels (p-value
<0.0001) compared to Group 1 (Table 2).
Serum globulin levels were significantly high (p-
value < 0.0001) in Group 2 (3 ± 0.46 g/dl) and Group 3
(3.6 ± 0.98 g/dl) when compared to Group 1 (2.43 ± 0.59
g/dl). Although there was no significant difference in the
levels of cholesterol, HDL and triglycerides but LDL level
was significantly higher (p-value < 0.001) in Group 3
(126.62 ± 20.9 mg/dl) compared to Group 1 (100.37 ±
15.33 mg/dl) and Group 2 (103.7 ± 20.9 mg/dl) (Table 2).
MRI and MRS data
Among 30 healthy controls, 21showed a normal MR im-
aging and 7 showed non-specific white matter changes.
In Group 2, 13 patients showed normal MRI whereas 7
patients showed non-specific white matter changes.
Group 3 is a heterogeneous group comprising patients
of HIV with tuberculomas (14 patients), progressive
multifocal leucoencephalopathy (4 patients), crypto-
coccal meningitis (2 patients) and 1 patient of suspected
intracranial malignancy.
There was no significant difference in the level of tCho
in FWM and BG among the three group studied. Pa-
tients of Group 3 were found to have significantly lower
levels of tNAA in BG (p-value < 0.05). Significantly high
levels of Glx (p-value < 0.05), tCr (p-value < 0.05) and
Lip09 +MM09 (p-value < 0.04) were seen in FWM of
Group 3. In BG, Glx, tCr and Lip09 +MM09 levels were
not significantly different among the three groups stud-
ied (Table 3).
Out of 14 HIV patients with CNS tuberculomas, 5 pa-
tients (35.7 %) showed lipid peak while 3 subjects
(21.4 %) showed lactate peak from the lesion. Out of 4
HIV patients with PML, one subject (25 %) showed lipid
peak and two (50 %) showed lactate peak from lesion
(Fig. 1). No lipid and lactate peak were observed in HIV
patient with suspected malignancy and cryptococcal
meningitis. We did not find any correlation of laboratory
parameters namely, CD4 count, hemoglobin, fasting
blood sugar, lipid profile, urea, creatinine or liver en-
zymes with neuro-biochemical levels.
Discussion
The immunosuppressed state in HIV patient makes
CNS vulnerable to opportunistic infection and tumors as
well as susceptible to damage from HIV itself [13]. MRI
of brain is a sensitive imaging modality for detection of
brain abnormalities in patients infected with HIV, how-
ever conventional MRI is not always sensitive for the de-
tection of the early stages of brain HIV infection [14].
No study till date has compared simultaneously healthy
controls, asymptomatic HIV patients and HIV patients
with CNS involvement by infection or malignancy. We
quantified the levels of neuro-biochemical to compare
with the results of previous studies.
Clinical evaluation and laboratory findings
It is expected that during the early stages of HIV infec-
tion, there are no neurological abnormality or anatom-
ical changes apparent on MRI. However, it is possible
that there may be some molecular and metabolic
changes occurring in the brain due to HIV infection.
Therefore asymptomatic HIV patients (Group 2) were
recruited to investigate whether the HIV infection itself
has some impact on brain neuro-biocehmicals even
without having overt involvement by infection or malig-
nancy. Majority of the patients of Group 3 were critically
ill and were having septicemia because of infection due
to underlying immunosuppression and septic shock.
Therefore these subjects showed significantly low systolic
blood pressure and increased respiratory rate as a compo-
nent of systemic inflammatory response syndrome (SIRS)
[15]. Lower CD4 count is associated with an increased risk
of opportunistic infection and increase risk of malignancy.
The Swiss HIV Cohort study reported that the risk of de-
veloping opportunistic infections is increased by 2.5 if the
CD4 count is between 51–200 cells/mm; this risk in-
creases to 5.8 for counts <50 cells/mm [16]. Various stud-
ies have demonstrated that lower CD4 counts are
associated with an increased prevalence of opportunistic
infections [17, 18]. This explains the probable presence of
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Table 2 Comparison of laboratory parameters among three groups
Variable Healthy controls Asymptomatic HIV HIV with CNS lesion p-value Post-hoc comparison
I vs II I vs III II vs III
Group 1 Group 2 Group 3
n = 30 n = 20 n = 21
Age 34.33 ± 12.5 36.95 ± 13.1 37.29 ± 10.6 0.63
Respiratory rate Per minute 15.8 ± 1.1 15.4 ± 1.1 16.6 ± 2.2 0.04 1.00 0.19 0.04
Systolic blood pressure in mmHg 121.67 ± 7.47 118.5 ± 7.42 112 ± 12.55 0.002 0.72 0.001 0.08
CD4 count/ul 257.40 ± 129.09 106.95 ± 86.94 0.0001
Hemoglobin gm/dl 14.49 ± 1.57 12.46 ± 1.28 10.68 ± 2.69 0.0001 0.001 0.001 0.01
Serum Calcium Meq/L 9.16 ± 0.6 8.56 ± 0.77 8.16 ± 0.64 0.0001 0.007 0.001 0.18
Serum sodium Meg/L 140.03 ± 4.04 138.05 ± 4.51 134.76 ± 5.52 0.0008 0.43 0.001 0.72
Serum albumin gm/dl 4.56 ± 0.77 3.89 ± 0.81 3.36 ± 0.61 0.0001 0.008 0.001 0.72
Serum globulin gm/dl 2.43 ± 0.59 3 ± 0.46 3.6 ± 0.98 0.0001 0.01 0.001 0.72
LDL mg/dl 100.37 ± 15.33 103.7 ± 20.9 126.62 ± 20.9 0.0001 1 0.001 0.001













various opportunistic infections like tuberculosis, PML
and cryptococcal meningitis in patients of Group 3.
Anemia is a frequent complication that occurs in 20 to
80 % HIV-infected persons and is associated with faster
disease progression and mortality [19]. HIV infection
may lead to anemia in many ways: changes in cytokine
production with subsequent effects on hematopoiesis
[20] decreased erythropoietin concentrations [21], op-
portunistic agents such as Mycobacterium avium com-
plex [22], administration of chemotherapeutic agents
such as zidovudine, ganciclovir [23] and cotrimoxazole
[24] and myelophthisis caused by cancers such as
Table 3 Comparison of concentration of neuro-biochemicals among three groups
Variable Healthy controls Asymptomatic HIV HIV with CNS lesion p-value Post-hoc comparison
I vs II I vs III II vs III








Frontal 9.29 ± 3.11 10.67 ± 3.8 10.99 ± 4.11 0.24 0.56 0.44 1
Basal ganglia 7.31 ± 0.47 7.29 ± 0.74 6.71 ± 0.64 0.01 1 0.01 0.03
Lip09 + MM09
FWM 5.59 ± 1.56 5.14 ± 1.79 8.69 ± 2.96 0.02 1 0.04 0.11
BG 5.87 ± 1.05 5.76 ± 1.95 5.59 ± 0.53 0.78 1 1 1
tCho
FWM 2.08 ± 0.70 2.50 ± 0.99 2.62 ± 0.78 0.07 0.26 0.12 1
BG 1.62 ± 0.17 1.68 ± 0.28 1.56 ± 0.16 0.27 1 1 0.33
tCr
Frontal 6.95 ± 2.56 8.9 ± 2.9 9.14 ± 3.04 0.02 0.05 0.05 1
Basal ganglia 6.95 ± 1.51 6.3 ± 1.77 6.62 ± 0.78 0.19 0.4 0.38 1
Glx (Glu + Gln)
FWM 15.0 ± 6.06 17.08 ± 5.6 20.4 ± 7.8 0.05 0.82 0.05 0.47
BG 13.99 ± 2.89 14.12 ± 3.6 13.92 ± 1.67 0.98 1 1 1
Oneway ANOVA followed by post-hoc comparison with Bonferroni correction
Fig. 1 In vivo 1H MRS spectrum from a left frontal white matter and b left basal ganglia of a healthy control, c tuberculoma in an HIV patient
and d white matter lesion from an HIV patient with Progressive Multifocal Leucoencephalopathy. Abbreviations: NAA, N-acetylaspartate;
Cho, choline; Cr, creatine;Lac, Lactate; Glx, Glutamate + Glutamine
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lymphosarcoma. Anemia has been associated with pro-
gression to AIDS and shorter survival times [25] for
HIV-infected patients.
Disturbances of electrolyte metabolism and endocrine
regulation like hyponatremia [26, 27], hypo- and hyper-
kalemia [28, 29] have been observed in HIV patients.
Hypocalcaemia, defined by serum calcium level less than
8.5 mg/dl [30], could be caused by HIV infection [31].
Diarrhea is a common condition seen in HIV and diar-
rheal diseases could also cause hypocalcaemia through
malabsorption and sepsis [32, 33]. It has long been noted
that hyponatremia is associated with pulmonary or cen-
tral nervous system (CNS) infections [34], gastrointes-
tinal sodium losses [35], adrenal insufficiency [36] and
renal disorders [37]. Importantly, a CNS or pulmonary
infection may result in a syndrome of inappropriate secre-
tion of antidiuretic hormone (SIADH), which plays a piv-
otal role in the presentation of hyponatremia [35, 38, 39].
Therefore hyponatremia can be correlated with disease
progression in HIV.
Serum albumin, is a plasma protein produced by the
liver, has a role in many physiologic processes, including
vasodilation, endothelial cell apoptosis, and antioxidant
reactions [40]. Individuals with conditions such as mal-
nutrition, chronic inflammation, enteropathy, or liver
disease can have reduced serum albumin concentrations
[40]. Several studies of HIV-infected individuals have de-
termined that hypoalbuminemia is associated with more
rapid progression to AIDS and all-cause mortality in de-
veloped countries [41, 42]. Globulin levels are also in-




NAA is a neuronal marker and is evenly distributed
throughout the cerebral cortex. Although its exact func-
tion is not known but it is widely accepted that de-
creased levels of NAA is a marker for neuronal loss.
NAAG is a neuron-specific dipeptide synthesized from
NAA and Glu by NAAG synthase, present in brain at its
highest concentration [43, 44]. NAAG and its precursor
NAA are proven by immune-histo-chemistry to be
present within the bodies of neuron [45]. The resonance
peak of the methyl group of NAAG at 2.04 ppm strongly
overlaps with methyl resonance of NAA in brain MRS.
Our findings are in agreement with a previous report
[46], which showed decreased tNAA levels in BG but
not in FWM of acutely infected HIV patients. BG com-
prised of neuronal cell bodies and FWM is composed of
mainly nerve fibers. The observation of decreased levels
of tNAA in BG may indicate significant neuronal loss in
this region compared to FWM.
In the present study, a significant increase of tCr was
seen in FWM in Group 3 compared to Groups 1 and 2.
This may be due to two possible factors: (i) glial cells
contain higher Cr content than neurons therefore, a cell
population change results in change of Cr level and, (ii)
the equilibrium between PCr and Cr in creatine kinase
reaction may change due to the disease progression [47].
Previous studies have shown changes in Cr levels in
brain of patients with HIV infection. Ernst et al. reported
decreased concentration of Cr in right basal ganglia in
patients with HIV and progressive cognitive impairment
with motor dysfunction [48]. In a study on ART naïve
HIV patients Chang et al. reported an increase in Cr in
frontal white matter and correlation with CD4 count
[49]. These results suggest region specific changes in Cr
metabolism in HIV patients; however, further studies are
required to substantiate these findings. Moreover, most of
the previous studies analyzed ratios of neuro-biochemicals
with respect to Cr, assuming that the concentration of Cr
do not change significantly [5–7, 50, 51]. However, it has
been shown that Cr levels can increase with age and
trauma as a hyperosmolar response and some brain path-
ologies like stroke, tumor, lymphoma, toxoplasmosis are
characterized by reduced Cr [45].
Glutamate and glutamine (Glx)
Metabolically Glu is stored as glutamine (Gln) in glial
cells, and the balanced cycling between these two neuro-
biochemicals is essential for normal functioning of brain
cells. Astrocytes are responsible for uptake of most
extracellular Glu via the high-affinity Glu transporters
GLT1 and GLAST, and additionally have a vital role in
preserving the low extracellular concentration of Glu
needed for proper receptor-mediated functions, as well
as maintaining low concentrations of extracellular Glu
to prevent excite-toxicity [52, 53]. Therefore Gln is an
astrocyte marker and Glu is an important neurotrans-
mitter [45]. Glutamate release is subject to calcium regu-
lation, and CD38 is an enzyme in astrocytes involved in
intracellular calcium signal. CD38 up-regulation was
demonstrated by immune-histo-chemical analysis in
brain tissue from HIV encephalopathy (HIVE) patients
[54]. Activated astrocytes increase CD38 expression after
IL-1β treatment, and this up regulation is mediated by
the MAPK and NF-kB signal cascades [55]. Thus the
resulting over expression of CD38 partially occurred due
to the evoked Glu release, which was in turn caused by
elevated Ca2+ influx [56]. However, the role of increased
levels of Glu in CSF or plasma as an useful indicator of
HIV-associated excite-toxicity remains to be investigated.
Experimental evidence suggests that excite-toxicity might
play a major role in HIV-induced neuro-degeneration.
Ferrase et al. showed increased Glu levels in CSF of HIV
patients, compared to healthy subjects, also in patients
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with Alzheimer-type dementia, and patients with other
neurologic disorders [9]. Increased glutamate levels in the
CSF and plasma of HIV-infected patients and the glutam-
ate levels positively correlated with the degree of dementia
and brain atrophy [10]. Nonetheless, it is widely accepted
that brain metabolite dysregulation occurs early in HIV
infection [57] and persists in the setting of chronic and
stable disease [58]. Clinical studies using 1H MRS to
evaluate the metabolite levels in early versus chronic cog-
nitively normal HIV+ subjects showed a reduction in the
Glx levels of HIV+ subjects compared to controls [57, 59].
It should be noted that Ernst et al. [60] showed no sig-
nificant increase in white matter Glu levels after adjust-
ing p-value for multiple comparison.
The present study showed increase in Glx in FWM of
HIV patients with CNS lesions compared to asymptom-
atic HIV patients and healthy controls. Metabolism and
regulation of Glu and Gln is a complex process in pa-
tients with HIV and requires further studies to under-
stand these changes in relation with HIV infection.
Choline and myo-Inositol
myo-Inositol (mI) is a known glial marker. Many previ-
ous studies have shown either an increase in mI [6, 51]
or no change in mI levels [7, 57]. The present study does
not reflect any change in the brain mI levels. Cho is con-
sidered to be a marker of cell membrane and previous
studies have reported variable results. While most of the
studies showed increased Cho/Cr ratio with HIV infec-
tion [5, 50], few depicted no change in Cho/Cr ratio with
HIV infection [6, 7]. We did not find any significant
changes in choline levels in Group 2 and Group 3 com-
pared to Group 1.
Lipid and macromolecules
The present study showed significant increase in Lip09/
MM09 signal at 0.9 ppm in FWM in HIV patients with
CNS lesion compared to healthy subjects. Over 20 % of
the dry weight of brain is lipid and these macromole-
cules do not appear unless some pathological process
liberates the MR visible triglycerides and long chain fatty
acids as seen in infection, inflammation, necrosis or
stroke [45]. Salvan et al. conducted a study on HIV in-
fected children older than 2 years using 1H MRS to
study their cerebral metabolism and to identify meta-
bolic profiles in relation to different stages of the disease.
A significant increase of the proportion of the lipid sig-
nals (p-value <0.05) was found in all HIV-infected chil-
dren compare to HIV negative controls. In our study,
Group 3 showed increased levels of Lip09/MM09 in
FWM compared to healthy controls. In a study by Roc
et al., the lipid and lactate/Cr ratio was significantly ele-
vated in HIV positive subjects irrespective of the level of
neuro-cognitive impairment on the MRS study of len-
ticular nuclei [61].
There are some limitations of the present study; the
low number of patients in Group 3 which is primarily
due to reason that these patients were on life support
and with altered sensorium posing a difficulty to subject
them to MRS. The number of patients with tuberculo-
mas, PML, cryptococcal meningitis and suspected intra-
cranial malignancy were very low and hence sub-group
analysis could not be carried out. Further, it is difficult
to conclude with certainty if the neuro-biochemical
changes seen were either caused by the varying tissue
composition in different MRS voxel or the neuro-
biochemical change was associated with the cell popula-
tion change during the diseases progression. In MRS
there is possibility of partial volume effect from dif-
ferent tissues, which is difficult to avoid in some ana-
tomical areas with cuboid shaped voxel. In our study,
the voxel size and location was adjusted to match the
target anatomical area as accurately as possible, how-
ever, there is possibility of varying tissue composition
being included in the voxel. In addition, compara-
tively smaller voxel size might have resulted into low
signal to noise ratio in some of the spectra obtained.
For example, in case of voxel localization in FWM,
there is possibility of inclusion of gray matter. We
have not acquired the tissue composition data for
each voxel to correct for these partial volume effects.
In addition, it is difficult to differentiate between lipid
and lactate signal at TE of 35 ms.
Conclusion
The results of the present study showed significant in-
crease in Glx and tCr in FWM of HIV patients with
CNS lesion compared to asymptomatic HIV patients
and healthy controls. In BG, there is significant reduc-
tion in tNAA. Asymptomatic HIV patients do not have
significant alteration in brain neuro-biochemicals com-
pared to healthy controls. Our findings support excito-
toxicity effect of increased Glx in HIV associated dementia
and region specific metabolic changes in brain associated
with HIV infection.
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